Skip to content

Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Pain in Nasopharyngeal Carcinoma Patients Undergoing Endoscopic Nasopharyngectomy

Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Pain in Nasopharyngeal Carcinoma Patients Undergoing Endoscopic Nasopharyngectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125601
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-05-28
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative pain

Interventions

Intervention Group (Stimulation Group):Patients in the stimulation group were administered intraoperative taVNS throughout the procedure
Control Group (Sham Stimulation Group):Intraoperative taVNS sham stimulation

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily sign the informed consent form. 2.Aged 18 to 75 years. 3.ASA physical status Grade I–III. 4.Scheduled for endoscopic nasopharyngectomy under general anesthesia. 5.No communication barriers, and educational level sufficient to complete preoperative assessments.

Exclusion criteria

Exclusion criteria: 1.Contraindications to taVNS: implantation of a cardiac pacemaker or concurrent use of other electrical stimulation therapies; inability to cooperate with treatment (e.g., dementia, Parkinson’s disease, epilepsy, etc.); excessive skin lesion area; infection or skin injury at the stimulation and puncture sites. 2.Patients with severe primary or secondary diseases that may significantly increase surgical risk, delay or interrupt surgery. These include but are not limited to: Child–Pugh class C liver failure; end-stage renal disease with persistent or uncorrectable electrolyte disturbances; severe hematological diseases (e.g., severe coagulation disorders); severe respiratory failure requiring respiratory support; severe cardiac insufficiency or active/progressive infectious diseases. 3.Administration of drugs known to affect autonomic nervous function within the past 1 week, including sedatives or antidepressants. 4.Current participation or participation in other clinical trials within the previous 12 weeks. 5.Patients undergoing intraoperative tracheotomy. 6.Preoperative chronic pain lasting more than 3 months or requiring long-term medication. 7.Patients requiring intraoperative temporal muscle flap repair.

Design outcomes

Primary

MeasureTime frame
Intraoperative opioid consumption;Time-Weighted Average Pain Score over 48 Postoperative Hours;

Secondary

MeasureTime frame
Rescue analgesia rate;NRS pain scores;Activities of Daily Living (ADL) scale score;Incidence of moderate-to-severe pain (NRS = 4) within 48 hours postoperatively;Postoperative length of hospital stay;Cumulative opioid consumption within 48 hours postoperatively;Quality of Recovery-15 (QoR-15) score;Time to extubation;Rate of premature PCA pump discontinuation;Incidence of pricking sensation at the stimulation site;Incidence of dizziness;Rescue analgesic dosage;

Countries

China

Contacts

Public ContactDezhao Liu

Fifth Affiliated Hospital, Sun Yat-Sen University

sumsldz@163.com+86 15360884591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026